Sign In
Last checked at 
5 May 2011 07:00
For immediate release | 5 May 2011 |
Futura Medical plc
("Futura" or "the Company")
AGM Statement
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will hold its Annual General Meeting in London later today.
At the meeting, Dr William Potter, the Company's Chairman, will make the following statement:
"The current financial year has started well for Futura, and we look forward to the commercial launch of PET500 and to the award of the CE mark for CSD500.
"Futura is on the threshold of becoming a company that benefits from significant royalty income. We look to the future with confidence."
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
| Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / Jessica Fontaine | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Follow the stocks
